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The microtubule-associated proteins MAP1A and MAP1B are related but distinct multi-subunit protein complexes that consist of heavy and
light chains. The predominant forms of these complexes are homotypic, i.e. they consist of a MAP1A heavy chain associated with MAP1A light
chains or a MAP1B heavy chain associated with MAP1B light chains, respectively. In addition, MAP1A and MAP1B can exchange subunits and
form heterotypic complexes consisting of a MAP1A heavy chain associated with MAP1B light chains which might play a role in a transition
period of neuronal differentiation. Here we extend previous findings by confirming that heterotypic MAP1B heavy chain-MAP1A light chain
complexes also exist in the developing murine brain. We show that these complexes form through interaction of homologous domains conserved
in heavy and light chains of MAP1A and MAP1B. Likewise, conserved domains of the MAP1A and MAP1B light chains account for formation of
light chain heterodimers. By yeast 2-hybrid analysis we located the light chain binding domain on the heavy chain to amino acids 211–508,
thereby defining a new functional subdomain.
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The high molecular mass microtubule-associated proteins
1A (MAP1A) and 1B (MAP1B) are expressed in mammalian
brain in a reciprocal pattern, MAP1B being elevated during
early stages of neuronal development in the brains of embryos
and newborn mice and MAP1A reaching its peak in the adult
brain, when neuronal differentiation is complete and MAP1B
levels decrease [1,2]. MAP1B is essential for normal brain
development [3–6] and plays a role in axon guidance and
elongation [6–9]. Much less is known about the function of
MAP1Awhich is thought to replace MAP1B in mature neurons.
MAP1A and MAP1B are multi-subunit protein complexes
consisting of one heavy chain (HC) and at least one light chain
(LC). In each case, heavy and light chains are generated byAbbreviations: HRP, horse radish peroxidase; MAP, microtubule-associated
protein; MH, MAP1 homology; HC, heavy chain; LC, light chain; SDS-PAGE,
SDS-polyacrylamide gel electrophoresis
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and LC2 from the MAP1A precursor and HC1 and LC1 from
MAP1B. MAP1A and MAP1B share 3 domains of sequence
homology [11] which we call MAP1 homology (MH) 1, 2, and
3 (Fig. 1A). These are located at the N- and C-termini of the
heavy chains (MH1 and 2, respectively) and in the C-terminal
half of the light chains (MH3). MH3 has 3 important functions:
it can bind to F-actin [12,13] and might thus be responsible for
the observed interaction of MAP1A and MAP1B with
microfilaments [14–16], it mediates dimerisation of LC1 [12],
and it contains the domain through which the light chain binds
to the MH1 domain of the heavy chain [12,17]. The N-termini
of LC1 and LC2 each contain a microtubule binding domain
which is not homologous in sequence and has distinct effects on
microtubule organization and stability [12,13]. These and other
findings suggest that LC1 and LC2 are active subunits of the
MAP1 complexes and determine the distinct functional
properties of MAP1A and MAP1B [12,13,18]. The heavy
chains might act as regulatory subunits [12].
The structural relationship of MAP1A andMAP1B in crucial
functional domains, the similar organization of the multi-
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periods in brain development both proteins are expressed at
equal levels [1,2] and even in the same cells [18] raise the
possibility that not only homotypic complexes (HC1+LC1 or
HC2+LC2), but also heterotypic complexes (HC1+LC2 or
HC2+LC1) could be formed. Indeed, the existence of
heterotypic complexes consisting of HC2 and LC1 has been
reported [1,19]. Since LC1 and LC2 have distinct functional
properties these heterotypic complexes might be of specialimportance during the transition from developing to mature
neurons, but it is unclear how they are formed.
Here we report that the light chains of MAP1A and MAP1B,
LC2 and LC1, can form heterodimers and that LC2, in addition
to LC1, can interact directly with the heterologous heavy chain
of MAP1B. We propose that each of these heterologous
interactions can provide a mechanism for the formation of
heterotypic MAP1 complexes. We also could narrow down the
binding domain for LC1 and LC2 in the N-terminus of the
heavy chain, thus defining a functional subdomain of MH1.
2. Materials and methods
2.1. Constructs
cDNA constructs for expression of the various MAP1A and MAP1B
domains in PtK2 cells have been described previously [12,13]. For yeast 2-
hybrid β-galactosidase assays based on the Matchmaker LexA system
(Clontech) we inserted fragments containing MH3A and MH3B into the bait-
fusion vector pLexA to yield constructs for the expression of the respective
MH3 domain fused to the DNA binding domain of the 2-hybrid system. Briefly,
the multiple cloning site of the bait-fusion vector pLexA (Clontech) was
modified by inserting the double-stranded oligonucleotide 5′-AATTCCC-
CATGGGGGCCC-3′ between the EcoR1 and Xho1 sites to yield pLexARN.
This vector encodes the LexA DNA binding domain (DNA-BD) of the 2-hybrid
system. A construct containing myc-tagged MH3B (Fig. 1A; [12]) was cut with
Hpa1 and Apa1 to remove the C-terminal myc-tag and re-ligated using theFig. 1. The MH3 domain of LC2 can bind to the MH1 domain of MAP1B. (A)
The MAP1A and MAP1B polyprotein precursors and the corresponding heavy
and light chains (HC2 and LC2 for MAP1A; HC1 and LC1 for MAP1B) are
indicated, as well as the sites of cleavage of the polyprotein precursors (arrows),
the microtubule binding domains of the light chains (MT), and the domains of
sequence homology (MH1,MH2,MH3, dark shading). Numbers indicate amino
acid positions for rat MAP1A [11,24] and MAP1B (according to database entry
XM_215469). Constructs (amino acids): LC1 (2212–2461); LC2 (2778–2998);
MH1B (1–508); NT-HC1 (1–731); ΔNT-HC1 (211–692); MH3B (2337–2461);
MH3A (2874–2998). (B) Whole brain protein lysates of 13-day-old mice (input)
were immunoprecipitated (IP) with an antibody against the MAP1A light chain
(anti-LC2) or without antibody (no ab) as negative control. Precipitates were
fractionated on 4.5% gels, blotted and probed (WB) with antibodies against the
MAP1B (anti-HC1) or MAP1A (anti-HC2) heavy chain. The position of the
respective heavy chain on the blot is indicated. A fraction of MAP1B heavy
chain present in the lysate can be coimmunoprecipitated with anti-LC2. (C)
Whole brain protein lysates of 21-day-old mice were immunoprecipitated (IP),
fractionated on 15% gels, and analysed by immunoblotting (WB) with the
indicated antibodies. The position of LC2 on the blot is indicated. The MAP1A
light chain was precipitated from brain lysates with anti-LC2. LC2 was also
coimmunoprecipitated with anti-HC1. To rule out that the LC2 signal after
precipitation with anti-HC1 was merely due to reaction of the secondary
antibody with the light chain of the anti-HC1 antibody which is similar in size to
LC2, controls with secondary antibody only (2nd ab only) were carried out. No
signal was detected in these cases. The antibody against an unrelated protein
(anti-unrel) is specific for the chicken FIP-2 protein [22]. (D) Approximately
1μg of recombinant LC1 or LC2 were fractionated on a 15% gel, blotted and
probed with amido black to reveal the presence of the 2 proteins on the blot or
with anti-LC2 which exclusively reacted with LC2. (E) Interaction of MAP1A
and MAP1B domains. Yeast cells expressing the indicated combinations of
activation domain-fusion proteins of the MAP1B heavy chain (NT-HC1 orΔNT-
HC1) and the MH3 domains of LC1 (MH3B) or LC2 (MH3A) fused to a DNA-
binding domain were analyzed for β-galactosidase activity. Cells containing
plasmids encoding the DNA-binding domain (DNA-BD) instead of the MH3/
DNA-binding domain fusion proteins were used as negative controls. Bars
represent the mean values of β-galactosidase activity determined in Miller units.
Results were measured in triplicates in three independent experiments.
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ly, a fragment containing MH3B now flanked by Nco1 and Apa1 sites was
excised and cloned into the Nco1 and Apa1 sites of pLexARN to yield a
construct for the expression of the MH3B domain fused to the transcription
factor DNA binding domain of the 2-hybrid system in yeast. The corresponding
MH3A domain of MAP1A (Fig. 1A) was amplified by PCR using a construct
containing LC2 [13] as template and primers 5′-GATCGAATTCCCCA-
CAGCCTTGGGCTCCAAG-3′ and 5′-GATCCTCGAGCTAGAACT-
CAATCTTGCAGG-3′, cut with EcoR1 and Xho1 and inserted into the
EcoR1 and Xho1 sites of pLexARN to yield a construct for the expression of
the MH3A domain fused to the transcription factor DNA binding domain of the
2-hybrid system in yeast. Constructs expressing NT-HC1 and ΔNT-HC1 fused
to the activation domain of the transcription factor of the 2-hybrid system were
obtained in a 2-hybrid screen performed using MH3B as bait and a cDNA
library prepared from 19-day mouse embryos (Clontech) according to the
manufacturer's recommendations. For expression of recombinant 6xHis-tagged
proteins in E. coli, cDNA fragments were cloned into a derivative of pET15b
(Novagen). LC2 was also cloned into pET32a (Novagen) to obtain the S-tagged
variant. The correct sequence of all constructs was confirmed.
2.2. Immunofluorescence microscopy
Cell culture, DNA transfection and immunofluorescence microscopy of
PtK2 cells were carried out as described [13]. Primary antibodies: affinity
purified polyclonal rabbit anti-myc antibody [20] at a concentration of 1μg/ml;
monoclonal rat anti-HA antibody 3F10 (Boehringer Mannheim) at a dilution of
1:1000; monoclonal mouse anti-tubulin antibody B-5-1-2 (Sigma) at 1:500; a
mixture of monoclonal mouse anti-β-actin antibodies AC-15 and AC-74
(Sigma) each at a dilution of 1:200. Secondary antibodies were Alexa Fluor 488
labeled anti-rabbit, Alexa Fluor 568 labeled anti-mouse and Alexa Fluor 350
labeled anti-rat secondary antibodies (Molecular Probes) used at dilutions of
1:500–1:1000.
2.3. β-galactosidase assay
β-galactosidase assays were based on the Matchmaker system (Clontech).
Three colonies of each transformant were grown overnight at 30°C in 2ml
dropout-induction medium (6.7g/l yeast nitrogen base, 1× dropout supplements,
2% (w/v) galactose; 1% (w/v) raffinose, 26mM Na2HPO4, 25mM NaH2PO4).
4ml of fresh induction medium were inoculated with 1ml overnight culture,
grown at 30°C to an OD600 of 0.5 to 0.8. Exact OD600 was recorded, cells were
collected by centrifugation, washed with Z-buffer (60mM Na2HPO4, 40mM
NaH2PO4, 10mM KCl, 1mMMgSO4, pH 7.0), and resuspended in 100μl of Z-
buffer. 700μl of Z-buffer with 0.27% (v/v) β-mercaptoethanol, one drop of
0.1% SDS and two drops of CHCl3 were added, mixed thoroughly and
equilibrated for 15min at 30°C. Enzyme reaction was started by addition of
160μl freshly prepared ortho-nitrophenyl-β-D-galactopyranoside (4mg/ml).
Reactions were stopped by addition of 400μl 1M NaCO3 when samples turned
yellow and time was recorded. Samples were centrifuged for 15min at
14000rpm and the OD420 was recorded. β-galactosidase activity was calculated
in Miller units: 1U=1000×OD420/t×V×OD600).
2.4. Coimmunoprecipitation
Whole brains (500mg wet weight) of C57BL/6 mice were homogenized in
1ml of ice-cold TEN buffer (100mM Tris/HCl (pH 7.5), 100mM NaCl, 10mM
EDTA, 0.1mM DTT) containing a mixture of protease inhibitors (Roche) with a
Potter–Elvehjem homogenizer with a motor driven Teflon pestle and incubated
on ice for another 30min. Immunoprecipitations were carried out on ice as
described [12]. Finally, samples were eluted by boiling in 30μl SDS sample
buffer containing 5% 2-mercaptoethanol, fractionated on denaturing gels by
SDS-PAGE, blotted, and analyzed as described [21]. Antibodies: polyclonal
rabbit anti-LC2 serum [13] at a dilution of 1:100 in precipitation and 1:1000 in
blot analysis; affinity purified polyclonal rabbit anti-HC1 antibody [6] at 1:25 in
precipitation and 1:800 in blot analysis; monoclonal mouse anti-HC2 antibody
HM-1 (Biogenesis) at 1:500; affinity purified polyclonal rabbit anti-FIP-2
antibody [22] at 1:25.2.5. Blot overlay assay
For detection of protein interaction by blot overlay, recombinant proteins
were expressed in E. coli, purified as described [13], fractionated by SDS-
PAGE, and blotted onto nitrocellulose membranes (BA83, 0.2μm pore size,
Whatman, Schleicher and Schuell). Blots were stained with Ponceau Red to
verify that equal amounts of recombinant proteins were loaded on the gel and
present on the blot and subsequently cut into strips each containing only one
protein. Strips were handled individually in the following procedures. Strips
were blocked in buffer A (150mM NaCl, 0.25% Tween 20 in PBS) containing
2% bovine serum albumin for 1h, washed 3 times for 5min in buffer A,
incubated with or without 10μg/ml LC2 with S-tag in buffer A containing 1%
bovine serum albumin for 2h, washed again, probed with INDIA HisProbe-HRP
(Pierce; 1:7000) or horse radish peroxidase (HRP) conjugated S-protein
(Novagen; 1:40000) for 1h, and developed according to the manufacturer's
recommendation.3. Results
3.1. The light chain of MAP1A can bind to the heavy chain of
MAP1B: heterologous interaction of conserved domains MH1
and MH3
Studies carried out on MAP1A andMAP1B revealed that the
respective light chains can interact with N-terminal domains of
the heavy chains [17,19]. We showed for MAP1B that the
crucial domains for this interaction are MH1B and MH3B [12].
MH1 and MH3 are (by definition) conserved in MAP1A and
heterologous complexes consisting of HC2 and LC1 have been
detected in the brain [1,19]. Evidence for the existence of the
complementary complex, HC1+LC2 was limited due to the low
level of expression of this complex [1]. To confirm that such
complexes exist in the brain we performed coimmunoprecipita-
tion assays using either anti-LC2 or anti-HC1 antibodies and
brain protein lysates from 13- to 21-day-old mice. At this age
MAP1B expression is still sufficiently high despite its decline
from perinatal levels and MAP1A levels have already increased
to about 50% of adult brain so that both proteins are expressed
at easily detectable levels. At these stages we detected a small
fraction of MAP1B heavy chain HC1 to be associated with LC2
(Fig. 1B and C), both when immunoprecipitations were carried
out with anti-LC2 (Fig. 1B) or with anti-HC1 antibodies (Fig.
1C). A number of controls were performed to ensure specificity
of these coimmunoprecipitations. Coimmunoprecipitating HC1
or LC2 were not detected in negative control precipitations
carried out either without antibodies or with antibodies against
an unrelated protein (Fig. 1B and C). To rule out that the 30-kDa
LC2 signal in precipitates of anti-HC1 was merely due to
reaction of the secondary antibody used in immunoblotting with
the light chain of the anti-HC1 antibody used in the
precipitation (which is similar in size to LC2), controls with
secondary antibody only were carried out. No signal was
detected in these cases (Fig. 1C). Moreover, the specificity of
the anti-HC1 antibody was demonstrated by its lack of
interaction with any proteins in extracts of MAP1B−/− mice
[6] and the specificity of the anti-LC2 serum was shown by
exclusive reaction with recombinant LC2 but not LC1 (Fig.
1D). These results confirm earlier indications [1] that
heterotypic HC1+LC2 complexes are expressed in the brain.
Fig. 2. LC2 can bind to the MH1 domain of MAP1B in vivo. (A–C), PtK2 cells
co-expressing HA-tagged MH1B (MH1B-HA) and myc-tagged LC2 (LC2-myc)
were analyzed by triple immunofluorescence microscopy using antibodies
against tubulin (A, anti-tubulin) the myc-tag (B, anti-myc), and against the HA-
tag (C, anti-HA). In the presence of LC2, MH1B was found to co-localize with
LC2 on microtubules (arrows). (D and E), cells expressing MH1B only
displayed a diffuse distribution of the protein throughout the cytoplasm
(compare panels D and E).
Fig. 3. Self-interaction of LC2 and interaction with conserved domains of
MAP1B. 3–6μg (depending on protein size, to achieve equal molarity) of the
indicated recombinant proteins (Vim, vimentin as negative control) were purified
and fractionated by SDS-PAGE. Replica blots were probed with INDIA
HisProbe to verify protein content on the blot, with S-protein alone to
demonstrate lack of interaction with His-tagged proteins (not shown), and
finally with purified recombinant S-tagged LC2 (LC2-S) followed by S-protein
as indicated. The latter revealed that LC2 can interact with MH1B, MH3B, LC1,
and with itself, but not with vimentin.
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heterologous complexes can be mediated by MH1B and MH3A
using the yeast two-hybrid system. Plasmids encoding fusion
proteins comprising MH1B fused to the activation domain of
the transcription factor were co-transfected with constructs
encoding the MH3 domains of LC1 or LC2, MH3B and MH3A,
respectively, fused to the DNA-binding domain of the
transcription factor into yeast cells harboring a lacZ reporter
gene. Transformants were analyzed for reporter gene expression
by measuring β-galactosidase activity. The MH3 domains of
both LC1 and LC2 were efficient in driving reporter gene
activity when expressed in the presence of a MAP1B heavy
chain fragment (Fig. 1E). Our analysis further showed that
amino acids 1–210 of the heavy chain are dispensable for
homotypic and heterotypic HC/LC interaction, thus defining a
functional subdomain of MH1. While we consistently observed
higher reporter gene activity withΔNT-HC lacking amino acids
1–210, indicating that this region could influence HC/LC
interaction, we cannot rule out that increased reporter gene
activity was due to slightly higher expression of the ΔNT-HC
construct. The specificity of the assay was shown by analyzing
transformants containing plasmids encoding the DNA-binding
domain only (instead of the MH3/DNA-binding domain fusionproteins) which resulted in background levels of β-galactosi-
dase activity. Auto-activation of MH1B and MH3 fragments
was excluded (not shown).
To confirm binding of LC2 to the MH1 domain of MAP1B in
vivo, we transiently expressed LC2 andMH1B in PtK2 cells and
analyzed the intracellular localization of the two proteins. Non-
neuronal PtK2 cells were chosen, because they contain only low
levels of endogenous MAP1B protein [12], which cannot
interfere with the proteins ectopically expressed. Myc-tagged
LC2 and HA-tagged MH1B were found to co-localize with
cellular microtubules (Fig. 2A–C). In contrast, cells expressing
MH1B alone revealed a diffuse cytoplasmic distribution of the
protein, demonstrating that this domain was not sufficient for
microtubule binding (Fig. 2D and E). Thus, microtubule binding
of MH1B in the presence of LC2 could be attributed exclusively
to themicrotubule binding activity of LC2 and demonstrated that
LC2 can simultaneously bind to microtubules and MH1B in
cultured cells. This is consistent with the fact that LC2 binds to
microtubules with its N-terminal domain [13] and toMH1Bwith
the C-terminalMH3A domain (Fig. 1E). Further confirmation of
direct interaction of LC2 with MH1B was obtained in blot
overlay assays using purified recombinant proteins (Fig. 3). A
purified protein fragment comprising MH1B on the blot was
specifically detected by the LC2 probe. Together, our results
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conserved MH1 and MH3 domains.
3.2. The light chains of MAP1A and MAP1B can form
heterodimers through interaction of their conserved MH3
domains
We have previously demonstrated that the light chain of
MAP1B can form homodimers or oligomers through interaction
of the MH3 domains of individual LC1 molecules [12]. In
addition, MAP1 complexes were found to consist of heavy and
light chains at a ratio of 1:2 [1,23]. Thus, heterotypic MAP1
complexes such as HC2/LC1/LC2 which were detected in the
brain [1] could be formed by binding of a light chain
heterodimer consisting of LC1 and LC2 to a heavy chain
molecule. We tested the potential direct interaction of LC2 with
LC1 using recombinant proteins in blot overlay experiments
(Fig. 3). In addition to binding to MH1B, the LC2 probe bound
to MH3B, to LC1, and to LC2. His-tagged vimentin was used as
negative control, to exclude unspecific interaction of the probe
with the His-tag.
To confirm these results in vivo, we co-expressed HA-tagged
MH3B and myc-tagged LC1 or LC2 in PtK2 cells. MH3B co-
localized with either light chain on microtubules (Fig. 4,
compare A–C and D–F). Since MH3B did not bind toFig. 4. LC2 can bind to the MH3 domain of MAP1B in vivo. (A–C), PtK2 cells co-ex
analyzed by triple immunofluorescence microscopy using antibodies against tubulin
same analysis carried out in PtK2 cells co-expressing HA-tagged MH3B (MH3B-H
domain of MAP1B was found to co-localize with the respective light chain on microt
domain to actin stress fibers as observed previously [12,13].microtubules on its own ([12] and Fig. 4G andH), its localization
on microtubules must be mediated by binding to the respective
light chain which in turn bound to microtubules through its N-
terminal microtubule binding domain [13]. Association of
MH3B with actin fibers in the absence of ectopically expressed
light chain (Fig. 4G and H) has been observed previously [12], is
due to a direct interaction with actin [13], and might be
responsible for the documented actin binding activity ofMAP1B
[14–16]. Additional nuclear localization of MH3B (Fig. 4H)
presumably is due to the small size of the protein, allowing it to
diffuse through nuclear pores. Together, our results showed that
LC1/LC2 heterodimers could form in vivo and in vitro through
interaction of their conserved MH3 domains.
4. Discussion
For a better understanding of MAP1A and MAP1B function
it is important to note that in addition to homotypic complexes
consisting of HC2/LC2 and HC1/LC1, respectively, heterotypic
complexes consisting of HC1/LC2 or HC2/LC1 can be found at
certain times in development, when both proteins are co-
expressed in the brain (Fig. 1B and C; [1,18,19]). Here we show,
that heterotypic complexes can form through interactions
between the MH1 and MH3 domains which are conserved
between MAP1A and MAP1B.pressing HA-tagged MH3B (MH3B-HA) and myc-tagged LC1 (LC1-myc) were
(anti-tubulin) the myc-tag (anti-myc), and against the HA-tag (anti-HA). (D–F),
A) and myc-tagged LC2 (LC2-myc). In the presence of LC2 or LC1, the MH3
ubules (arrows). (G and H), cells expressing MH3B only showed binding of this
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the MH1B domain of MAP1B we show not only that these
conserved domains mediate heterotypic complex formation, but
also that the light chain binding site on the heavy chain is
contained in the C-terminal half of MH1 consisting of amino
acids 211–508, thus defining a functional subdomain of MH1.
Previous studies have shown that MAP1A as well as MAP1B
complexes consist of one heavy and two light chains [1,23].
Two mechanisms are conceivable for the formation of such
complexes: either two light chains bind individually to separate
biding sites located in the conserved MH1 domains of the heavy
chains or the light chains form homo- or heterodimers and bind
as such to a single site on the heavy chain. For the first
mechanism to be operating one might expect to find two
binding sites of similar sequence in MH1 of which at least one
should be located between amino acids 211–508, identified as
light chain binding domain in the present study. However, no
such repeated sequences were found in MH1. On the other
hand, we have shown that light chains can form homodimers
[12] and heterodimers (this study), consistent with the
possibility that the second mechanism might underlie MAP1
complex formation.
We show here that one consequence of the conservation of
MH1 and MH3 domains in MAP1A and MAP1B is the capacity
of the two proteins to form heterotypic HC1/LC2 complexes
and LC1/LC2 heterodimers in addition to the respective
homotypic complexes and homodimers. This capacity to form
homo — as well as heterotypic complexes might endow
neurons with the possibility to fine tune the regulation of
microtubules and actin filaments [12,13] during a critical
transition period where neurons shift from axon extension to
axon stabilization and synaptogenesis.
Acknowledgement
This research was supported by a grant from the Austrian
Science Fund (Project No. F607).
References
[1] T.A. Schoenfeld, L.McKerracher, R. Obar, R.B. Vallee,MAP 1A andMAP
1B are structurally related microtubule associated proteins with distinct
developmental patterns in the CNS, J. Neurosci. 9 (1989) 1712–1730.
[2] C.C. Garner, A. Garner, G. Huber, C. Kozak, A. Matus, Molecular cloning
of microtubule-associated protein 1 (MAP1A) and microtubule-associated
protein 5 (MAP1B): identification of distinct genes and their differential
expression in developing brain, J. Neurochem. 55 (1990) 146–154.
[3] W. Edelmann, M. Zervas, P. Costello, L. Roback, I. Fischer, J.A.
Hammarback, N. Cowan, P. Davies, B. Wainer, R. Kucherlapati, Neuronal
abnormalities in microtubule-associated protein 1B mutant mice, Proc.
Natl. Acad. Sci. U. S. A. 93 (1996) 1270–1275.
[4] Y. Takei, S. Kondo, A. Harada, S. Inomata, T. Noda, N. Hirokawa, Delayed
development of nervous system in mice homozygous for disrupted
microtubule-associated protein 1B (MAP1B) gene, J. Cell Biol. 137 (1997)
1615–1626.
[5] C. Gonzalez-Billault, E. Demandt, F. Wandosell, M. Torres, P. Bonaldo, A.
Stoykova, K. Chowdhury, P. Gruss, J. Avila, M.P. Sánchez, Perinatal
lethality of microtubule-associated protein 1B-deficient mice expressingalternative isoforms of the protein at low levels, Mol. Cell. Neurosci. 16
(2000) 408–421.
[6] A. Meixner, S. Haverkamp, H. Wässle, S. Führer, J. Thalhammer, N.
Kropf, R.E. Bittner, H. Lassmann, G. Wiche, F. Propst, MAP1B is required
for axon guidance and is involved in the development of the central and
peripheral nervous system, J. Cell Biol. 151 (2000) 1169–1178.
[7] Y. Takei, J. Teng, A. Harada, N. Hirokawa, Defects in axonal elongation
and neuronal migration in mice with disrupted tau and map1b genes, J. Cell
Biol. 150 (2000) 989–1000.
[8] C. Gonzalez-Billault, J. Avila, A. Caceres, Evidence for the role of
MAP1B in axon formation, Mol. Biol. Cell 12 (2001) 2087–2098.
[9] C. Bouquet, S. Soares, Y. von Boxberg, M. Ravaille-Veron, F. Propst, F.
Nothias, Microtubule-associated protein 1B controls directionality of
growth cone migration and axonal branching in regeneration of adult
dorsal root ganglia neurons, J. Neurosci. 24 (2004) 7204–7213.
[10] J.A. Hammarback, R.A. Obar, S.M. Hughes, R.B. Vallee, MAP1B is
encoded as a polyprotein that is processed to form a complex N-terminal
microtubule-binding domain, Neuron 7 (1991) 129–139.
[11] A. Langkopf, J.A. Hammarback, R. Müller, R.B. Vallee, C.C. Garner,
Microtubule-associated proteins 1A and LC2, J. Biol. Chem. 267 (1992)
16561–16566.
[12] M. Tögel, G. Wiche, F. Propst, Novel features of the light chain of
microtubule-associated protein MAP1B: microtubule stabilization, self
interaction, actin filament binding, and regulation by the heavy chain,
J. Cell Biol. 143 (1998) 695–707.
[13] R. Noiges, R. Eichinger, W. Kutschera, I. Fischer, Z. Németh, G. Wiche, F.
Propst, MAP1A and MAP1B: light chains determine distinct functional
properties, J. Neurosci. 22 (2002) 2106–2114.
[14] D.J. Asai, W.C. Thompson, L. Wilson, C.F. Dresden, H. Schulman, D.L.
Purich, Microtubule-associated proteins (MAPs): a monoclonal antibody
to MAP1 decorates microtubules in vitro but stains stress fibers and not
microtubules in vivo, Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 1434–1438.
[15] B. Pedrotti, R. Colombo, K. Islam, Microtubule associated protein
MAP1A is an actin-binding and crosslinking protein, Cell Motil.
Cytoskelet. 29 (1994) 110–116.
[16] B. Pedrotti, K. Islam, Dephosphorylated but not phosphorylated
microtubule associated protein MAP1B binds to microfilaments, FEBS
Lett. 388 (1996) 131–133.
[17] C.L. Chien, K.S. Lu, Y.S. Lin, C.J. Hsieh, N. Hirokawa, The functional
cooperation of MAP1A heavy chain and light chain 2 in the binding of
microtubules, Exp. Cell Res. 308 (2005) 446–458.
[18] X. Mei, A.J. Sweatt, J.A. Hammarback, Microtubule-associated protein 1
subunit expression in primary cultures of rat brain, Brain Res. Bull. 53
(2000) 801–806.
[19] S.A. Kuznetsov, V.I. Rodionov, E.S. Nadezhdina, D.B. Murphy, V.I.
Gelfand, Identification of a 34-kD polypeptide as a light chain of
microtubule-associated protein-1 (MAP-1) and its association with a
MAP-1 peptide that binds to microtubules, J. Cell Biol. 102 (1986)
1060–1066.
[20] M. Tögel, G. Wiche, F. Propst, Evidence against structural and functional
identity of microtubule-associated protein MAP1B and proteoglycan
claustrin, FEBS Lett. 423 (1998) 254–258.
[21] J. Sambrook, E.F. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory
Manual2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, NY, 1989.
[22] H. Stroissnigg, M. Repitz, A. Miloloza, I. Linhartova, H. Beug, G. Wiche,
F. Propst, FIP-2, an IkappaB-kinase-gamma-related protein, is associated
with the Golgi apparatus and translocates to the marginal band during
chicken erythroblast differentiation, Exp. Cell Res. 278 (2002) 133–145.
[23] X. Mei, A.J. Sweatt, J.A. Hammarback, Regulation of microtubule-
associated protein 1B (MAP1B) subunit composition, J. Neurosci. Res. 62
(2000) 56–64.
[24] A. Nakayama, T. Odajima, H. Murakami, N. Mori, M. Takahashi,
Characterization of two promoters that regulate alternative transcripts in
the microtubule-associated protein (MAP) 1A gene, Biochim. Biophys.
Acta 1518 (2001) 260–266.
